Market Overview
The UK Biotechnology Market was valued at USD 22.00 Billion in 2024 and is projected to reach USD 41.47 Billion by 2033, growing at a CAGR of 7.22% during 2025–2033. Growth is driven by increasing chronic disease incidence, advancements in genomics and gene-editing technologies like CRISPR, rising investments, and expanding applications in healthcare, industrial biotechnology, and sustainable agriculture.
Study Assumption Years
- Base Year: 2024
• Historical Years: 2019–2024
• Forecast Period: 2025–2033
UK Biotechnology Market Key Takeaways
- Current Market Size: USD 22.00 Billion (2024)
• CAGR: 7.22%
• Forecast Period: 2025–2033
• Government support via UKRI & Innovate UK backed by a £1.1 billion annual budget strengthens early-stage biotech.
• The NHS Genomic Medicine Service processed 810,000+ genomic tests in 2024, up 8% from 2023.
• Reagents hold 45.8% market share, essential for diagnostics and genomics.
• DNA sequencing leads with 36.8% share, driven by next-gen sequencing and national genome projects.
• Healthcare applications account for 49.6% of total market demand.
Sample Request Link: https://www.imarcgroup.com/uk-biotechnology-market/requestsample
Market Growth Factors
The UK biotechnology market is primarily driven by the rising prevalence of chronic diseases requiring advanced treatments. Enhanced data analytics and bioinformatics capabilities improve R&D productivity, while strong funding landscapes—supported by Life Sciences Vision 2030 and R&D tax incentives—encourage private investments and international collaborations. Innovations in genomics and gene-editing technologies such as CRISPR further accelerate progress in precision health, rare disease therapies, and advanced medical research.
The push toward personalized medicine is another major catalyst. The NHS Genomic Medicine Service processed more than 810,000 genomic tests in 2024, marking a significant rise in clinical adoption. Large-scale initiatives like the 100,000 Genomes Project have positioned the UK as a global leader in medical genomics. This momentum attracts investment into gene therapy, molecular diagnostics, and cell therapy startups, enhancing commercialization of breakthrough therapies.
Sustainable agricultural biotechnology also contributes to market expansion. With increasing climate change challenges, biotech solutions are improving crop resilience, pest resistance, and yield optimization. Gene-edited crops, biopesticides, and biobased fertilizers lower reliance on chemicals, reduce environmental impact, and enhance food security. Public acceptance of gene-editing (69% support for food security applications) and advances in computational biology promote innovation across agricultural supply chains.
Market Segmentation
By Product Type:
- Instruments: Laboratory devices supporting biotech processes.
- Reagents: Essential chemicals powering diagnostics, genomics, proteomics (45.8% share).
- Software and Services: Digital tools and service-based solutions supporting biotech R&D and clinical operations.
By Technology:
- Nanobiotechnology: Nanoscale engineering in biological systems.
- Tissue Engineering & Regeneration: Technologies for repairing/replacing damaged tissues.
- DNA Sequencing: Leading technology with 36.8% share, essential for genomics & precision medicine.
- Cell-Based Assays: Experimental systems analyzing cellular behavior.
- Fermentation: Bioprocessing platform for biologics & industrial biotech.
- PCR Technology: Critical method for DNA amplification.
- Chromatography: Separation and analysis of complex compounds.
- Others.
By Application:
- Healthcare: 49.6% share, including diagnostics, drug discovery, gene therapy.
- Food & Agriculture: Yield improvement, pest resistance, sustainable farming.
- Natural Resources & Environment: Eco-solutions and environmental biotech.
- Industrial Processing: Bio-manufacturing and process optimization.
- Bioinformatics: Data-driven biological analysis tools.
- Others.
Regional Insights
London leads the UK biotechnology market due to strong R&D infrastructure, premier universities, biotech clusters, and high investment activity. The South East follows with major science parks and innovation hubs. The North West focuses on pharmaceutical manufacturing and bioprocessing, while regions such as East of England, Scotland, and South West specialize in life sciences, agri-biotech, and precision medicine. Specific regional market shares are not provided in the source.
Recent Developments & News
- March 2025 — Celex Oncology unveiled a first-of-its-kind cancer therapy targeting sodium overload in tumor cells.
• February 2025 — Biocon Ltd launched Liraglutide in the UK for diabetes & obesity, with expansion planned across Europe and the US.
• Sortera Bio introduced an AI-powered high-throughput discovery platform for accelerating therapeutic development.
• Tropic advanced CRISPR-based non-browning bananas, securing global regulatory approvals.
• January 2025 — Verdiva Bio raised USD 411 Million in Series A, targeting obesity and cardiometabolic diseases.
Key Players
- Celex Oncology
• Biocon Ltd
• Sortera Bio
• Tropic
• Verdiva Bio
Customization Note:- https://www.imarcgroup.com/request?type=report&id=24913&flag=E
If you require any specific information not currently covered within the report scope, we will provide it as part of the customization.
About Us
IMARC Group is a global management consulting firm assisting changemakers in market entry, feasibility, regulatory approvals, branding, pricing, procurement research, and competitive strategy.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201-971-6302
